A vinyl amine containing polymer comprises randomly distributed repeating monomer units having at least two of the following formulae:

##STR00001## wherein, R1 is a hydrogen atom or a methyl group; and wherein the vinyl amine containing polymer comprises repeating monomer unit III and/or IV in a total amount of from about 1.5 weight percent to about 8 weight percent based on a total weight of the polymer.

A vinyl amine containing polymer comprises randomly distributed repeating monomer units having at least two of the following formulae:

##STR00001## wherein, R1 is a hydrogen atom or a methyl group; and wherein the vinyl amine containing polymer comprises repeating monomer unit III and/or IV in a total amount of from about 1.5 weight percent to about 8 weight percent based on a total weight of the polymer.

Pharmaceutical compositions for and methods of treating an animal, including a human, and methods of preparing such compositions. The pharmaceutical compositions contain crosslinked amine polymers and may be used, for example, to treat diseases or other metabolic conditions in which removal of protons and/or chloride ions from the gastrointestinal tract would provide physiological benefits such as normalizing serum bicarbonate concentrations and the blood pH in an animal, including a human.

Pharmaceutical compositions for and methods of treating an animal, including a human, and methods of preparing such compositions. The pharmaceutical compositions contain crosslinked amine polymers and may be used, for example, to treat diseases or other metabolic conditions in which removal of protons and/or chloride ions from the gastrointestinal tract would provide physiological benefits such as normalizing serum bicarbonate concentrations and the blood pH in an animal, including a human.

Pharmaceutical compositions for and methods of treating an animal, including a human, and methods of preparing such compositions. The pharmaceutical compositions contain crosslinked amine polymers and may be used, for example, to treat diseases or other metabolic conditions in which removal of protons and/or chloride ions from the gastrointestinal tract would provide physiological benefits such as normalizing serum bicarbonate concentrations and the blood pH in an animal, including a human.

Pharmaceutical compositions for and methods of treating an animal, including a human, and methods of preparing such compositions. The pharmaceutical compositions contain crosslinked amine polymers and may be used, for example, to treat diseases or other metabolic conditions in which removal of protons and/or chloride ions from the gastrointestinal tract would provide physiological benefits such as normalizing serum bicarbonate concentrations and the blood pH in an animal, including a human.

Pharmaceutical compositions for and methods of treating an animal, including a human, and methods of preparing such compositions. The pharmaceutical compositions contain crosslinked amine polymers and may be used, for example, to treat diseases or other metabolic conditions in which removal of protons and/or chloride ions from the gastrointestinal tract would provide physiological benefits such as normalizing serum bicarbonate concentrations and the blood pH in an animal, including a human.

Pharmaceutical compositions for and methods of treating an animal, including a human, and methods of preparing such compositions. The pharmaceutical compositions contain crosslinked amine polymers and may be used, for example, to treat diseases or other metabolic conditions in which removal of protons and/or chloride ions from the gastrointestinal tract would provide physiological benefits such as normalizing serum bicarbonate concentrations and the blood pH in an animal, including a human.

A composition contains ethylenically unsaturated quaternary ammonium cations with acetate counterions, where each of the ethylenically unsaturated ammonium cations contain only one non-aromatic carbon-carbon double bond and the composition contains less than one mole-percent chloride relative to quaternary ammonium cations can be polymerized to form a cationic polymer acetate.

A composition contains ethylenically unsaturated quaternary ammonium cations with acetate counterions, where each of the ethylenically unsaturated ammonium cations contain only one non-aromatic carbon-carbon double bond and the composition contains less than one mole-percent chloride relative to quaternary ammonium cations can be polymerized to form a cationic polymer acetate.